Targeted Therapy for the Central Nervous System

Part I. Brief About Pathophysiology<br>1. Etiology and Treatment Challenges for Neurodegenerative Disorders<br>2. Etiology and Treatment Challenges for Neurotraumatic and Psychiatric Disorders<br>3. Barriers to Progress of Neurotherapeutics: Getting Drugs to the Brain<br> <br>Part II. Novel Formulation Strategies for Targeted Therapy<br>4. IGF-II Conjugated Nanocarrier for Brain Targeting<br>5. ApoE Potential in CNS Drugs Targeting and as CNS Therapeutic<br>6. Transferrin Functionalized Nanoparticles for Targeted Drug Delivery in Biological Systems<br>7. Surface Engineered Multimodal Magnetic Nanoparticles for Neurodegenerative Diseases<br>8. Tau Targeting Biomimetic Nanoparticles<br> 9. Stem Cell Therapy as a Novel Concept to Combat CNS Disorders<br>10. SR-B1 Receptor Targeting in CNS Disorders<br>11. β- and γ-secretases as Therapeutic Targets for Alzheimer&rsquo;s Disease<br>12. Minimally Invasive Nasal Depot (MIND) Technique for Direct BDNF AntagoNAT Delivery to the Brain<br>13. Immunosuppressive and Immunomodulatory Therapies<br>14. CRISPR/Cas9 Gene Editing: A New Hope for Alzheimer&rsquo;s Disease<br>15. Artificial Intelligence: Ways and Means for Central Nervous System (CNS) Delivery<br>16. Carbon Dots as Versatile Nano-architectures for the Treatment of Neurological Disorders<br> <br>Part III. Clinical Challenges and Regulatory Updates<br>17. Animal Models for Clinical Evaluation<br>18. Medical Device<br> Contributors: Abhishek Swarnkar, Viral Patel, Amit Patel, Manan Raval<br>19. Regulation of Nanomaterials and Nanomedicines for Clinical Applications<br>20. Regulatory Considerations for the use of Biomarkers and Personalized Medicine in CNS Drug Development<br>21. Regulatory Toxicology Testing for Pharmaceuticals<br>22. Emerging Challenges and Opportunities for Drug and Drug Product Registrations<br>23. CRISPR/Cas9 Gene Editing: A New Hope for Parkinson&rsquo;s Disease